Warner-lambert Company

Noramco Gmbh

Pfizer Corporation

Wyeth

Aeri Park

Joseph Francis Krzyzaniak

Timothy Andrew Woods

David Andrew Coates

Zheng Jane Li

Karen Sue Gushurst

Stephen Robert Byrn

Henry Grant Morrison, Ii

Petinka Ivanova Vlahova

Syed Muzafar Shah

Beat Theodor Weber

Peter Robert Rose

Anthony Francis Hadfield

Eric J Hagen

Michael William Winkley

Karen Sutherland

Kevin Quackenbush

Douglas Phillip Cox

Rex Alwyn Shipplett

Brenton William Russell

James Andrew Provost

George Laurence

Patrick Thomas Cyr

Abram Calderon

Marie L Reynolds

Kevin J Quackenbush

George Michael Laurence

Rex A Shipplett

Karen Wiggins Sutherland

Henry Grant Morrison

Marie Louise Reynolds

Henry Grant Ii Morrison

J F Pfizer Global Researchand Dev Krzyzaniak

Zheng J Pfizer Global Research And Develop Li

Novel forms of [R&#x2014;(R*,R*)]-2-(4-fluorophenyl)-&#x3b2;,&#x3b4;-Dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1-H-pyrrole-1-heptanoic acid hemi calcium salt designated Form XX, Form XXI, Form XXII, Form XXIII, Form XXIV, Forms XXV, Form XXVI, Form XXVII, Form XXVIII, Form XXIX, and Form XXX characterized by their X-ray powder diffraction, solid state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease.

Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)

Novel forms of [R&#x2014;(R*,R*)]-2-(4-fluorophenyl)-&#x3b2;,&#x3b4;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form XX, Form XXI, Form XXII, Form XXIII, Form XXIV, Form XXV, Form XXVI, Form XXVII, Form XXVIII, Form XXIX, and Form XXX, characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease.

Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-&#x3b2;,&#x3b4;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylmino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)

Novel forms of [R-(R*,R*)]-2-(4-fluorophenyl)-&#x3b2;,&#x3b4;-dihydroxy-5-(1-methylethyl)-3-phenyl-4 -[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form XX, Form XXI, Form XXII, Form XXIII, Form XXIV, Form XXV, Form XXVI, Form XXVII, Form XXVIII, Form XXIX, and Form XXX, characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease.

Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-&#x3b2;,&#x3b4;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoicacid calcium salt (2:1)

Hydrocodone bitartrate forms are disclosed which are useful as analgesic agents either in combination with or as replacements for hydrocodone bitartrate.

Hydrocodone polymorphs

Oxycodone.HCl polymorph forms are disclosed which are useful as analgesic agents either in combination with or as replacements for oxycodone.

Oxycodone polymorphs

Novel crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-&#x3b2;,&#x3b4;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.

Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-&#x3b2;,&#x3b4;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)

A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided.

Succinate salt of O-desmethyl-venlafaxine

Novel crystalline forms of &lsqb;R-(R*,R*)&rsqb;-2-(4-fluorophenyl)-&bgr;,&dgr;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-&lsqb;(phenylamino)carbonyl&rsqb;-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.

Crystalline forms of &lsqb;R-(R*,R*)&rsqb;-2-(4-fluorophenyl)-&bgr;,&dgr;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-&lsqb;(phenylamino)carbonyl&rsqb;-1H-pyrrole-1-heptanoic acid calcium salt (2:1)

Growing community of inventors

West Lafayette, IN, United States of America

Aeri Park